Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.44 |
| ▸ | PGR | P06401 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30832794 | 1.00 | BRD4 (0.49) | BRD4LMNAMAPTGAATDP1 | |
| SCHEMBL20773120 | 0.90 | LMNA (0.49) | BRD4LMNAMAPTGAATDP1 | |
| SCHEMBL30832777 | 0.90 | LMNA (0.49) | BRD4LMNAMAPTGAATDP1 | |
| SCHEMBL30832795 | 0.78 | TRIM24 (0.51) | LMNAMAPTGAATDP1MAPK14 | |
| SCHEMBL20772684 | 0.78 | TRIM24 (0.51) | LMNAMAPTGAATDP1MAPK14 | |
| SCHEMBL12361997 | 0.75 | LMNA (0.53) | BRD4LMNAPGRMAOBMEN1 | |
| SCHEMBL20773220 | 0.75 | BCL6 (0.51) | LMNAMAPTGAATDP1MAPK14 | |
| SCHEMBL30832785 | 0.75 | BCL6 (0.51) | LMNAMAPTGAATDP1MAPK14 | |
| SCHEMBL29859942 | 0.73 | LMNA (0.58) | BRD4LMNAMAPTGAAPGR | |
| SCHEMBL2522765 | 0.73 | LMNA (0.58) | BRD4LMNAMAPTGAAPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3679027-A1 | DIHYDROBENZIMIDAZOLONES | C4 Therapeutics, Inc. (US) | 2020-07-15 | — | — | EP | claimed |
| WO-2019043217-A1 | DIHYDROBENZIMIDAZOLONES | F. HOFFMANN-LA ROCHE AG (CH) | 2019-03-07 | — | — | WO | claimed |
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| CN-118206529-A | Dihydrobenzimidazolone | C4医药公司 | 2024-06-18 | — | — | CN | disclosed |
| US-20240109889-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| CN-111315735-B | Dihydrobenzimidazolone | C4医药公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11787802-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787802-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787802-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220289738-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2022-09-15 | — | — | US | disclosed |
| US-20220289738-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2022-09-15 | — | — | US | disclosed |
| US-11254672-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254672-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3679027-A1 | DIHYDROBENZIMIDAZOLONES | C4 Therapeutics, Inc. (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20200207764-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200207764-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| CN-111315735-A | Dihydrobenzimidazolones | C4医药公司 | 2020-06-19 | — | — | CN | disclosed |
| WO-2019043217-A1 | DIHYDROBENZIMIDAZOLONES | F. HOFFMANN-LA ROCHE AG (CH) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019043217-A1 | DIHYDROBENZIMIDAZOLONES | F. HOFFMANN-LA ROCHE AG (CH) | 2019-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207764-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | CRBN, CUL4A, ADRM1 | BRD4 301/4885LMNA 3835/4885MAPT 2761/4885 |
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | BRD4 301/4885LMNA 3835/4885MAPT 2761/4885 |
| US-20240109889-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | CRBN, CUL4A, ADRM1 | BRD4 301/4885LMNA 3835/4885MAPT 2761/4885 |
| US-20220289738-A1 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | CRBN, CUL4A, ADRM1 | BRD4 301/4885LMNA 3835/4885MAPT 2761/4885 |
| US-11787802-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | BRD4 301/4885LMNA 3835/4885MAPT 2761/4885 |
| US-11254672-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | BRD4 301/4885LMNA 3835/4885MAPT 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.